Thermo Fisher Bioproduction Insights

1. Secure Your Custom Media Supply With Capacity And Quality You Can Trust 7/17/2026

   A resilient media supply strategy helps reduce operational risk. Gain insight into how scalable manufacturing, quality alignment, and supplier qualification can strengthen continuity.

2. Is It Better To Scale Up Or Scale Out Your Cell Culture Platform? 6/29/2026

   Take a look at how adherent cell culture expansion affects space, labor, costs, contamination risk, and sustainability, helping teams weigh when a larger-footprint approach stops making sense.

3. Engineering The Future Of Antibody-Drug Conjugates 6/26/2026

   As ADCs expand into broader use, upstream process design is becoming a competitive advantage. Discover how smarter media strategies and data-driven decision-making are helping teams reduce risk.

4. Q&A: From Trial-And-Error To Predictive Protein Production 6/26/2026

   Speed in protein production starts with better inputs and stronger process analytics. Learn how a three-part strategy helps teams reduce rework and move from guesswork to predictable outcomes.

5. Exploring The Future Of Cell Expansion In Cell Therapy Manufacturing 6/26/2026

   As cell therapy scales, success depends on more than clinical promise. Smarter expansion strategies, automation, and flexible manufacturing platforms are becoming critical for improving consistency.

6. Delivering Critical Therapies With Speed And Safety 6/26/2026

   Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.

7. A Clear Path To Rapid, Consistent Biosimilar Development 6/23/2026

   Faster timelines don’t have to come at the expense of quality or consistency. Discover proven strategies to generate stable, high-performing cell lines while reducing risk and supporting reliable scale-up.

8. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

   Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

9. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

   Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

10. Closing The QC Gap For mAbs: Rapid Answers Without Compromising 6/9/2026

    Monoclonal antibodies are complex biologics requiring precise analytical strategies to monitor critical quality attributes and impurities, with molecular assays like qPCR supporting sensitive detection, product integrity, and regulatory compliance.